ICER Suggests Price Of $2,500-$8,300 For Biogen’s Aducanumab
Cost Watchdog Sees Insufficient Data To Show Health Benefit
Given mixed Phase III results for the Alzheimer’s drug and potentially severe side effects for the once-monthly infused therapy, ICER’s recommendation came in below analyst expectations.
